Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. [electronic resource]
Producer: 20180213Description: e551 p. digitalISSN:- 2044-5385
- Animals
- CD4-Positive T-Lymphocytes -- metabolism
- CD8-Positive T-Lymphocytes -- metabolism
- Cell Count
- Cell Line, Tumor
- Humans
- Imatinib Mesylate -- administration & dosage
- Interleukin-7 -- antagonists & inhibitors
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Lymphopenia -- genetics
- Mice
- Phosphorylation -- drug effects
- Receptors, Antigen, T-Cell -- genetics
- STAT5 Transcription Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.